Shares of Histogenics Corp (NASDAQ:HSGX) traded up 21.6% during mid-day trading on Thursday . The company traded as high as $0.75 and last traded at $0.90. 606,012 shares were traded during trading, a decline of 39% from the average session volume of 998,330 shares. The stock had previously closed at $0.74.
A number of analysts recently issued reports on the company. Zacks Investment Research lowered Histogenics from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. HC Wainwright restated a “buy” rating and set a $3.50 target price on shares of Histogenics in a research report on Monday, August 13th. Brookline Cap M restated a “buy” rating on shares of Histogenics in a research report on Wednesday, August 1st. Needham & Company LLC boosted their target price on Histogenics to $5.00 and gave the stock a “buy” rating in a research report on Thursday, September 6th. Finally, BTIG Research cut Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 target price for the company. in a research report on Wednesday, September 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $3.45.
The stock has a market capitalization of $15.93 million, a P/E ratio of -0.81 and a beta of 1.82.
Histogenics (NASDAQ:HSGX) last posted its earnings results on Thursday, August 9th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.10. Sell-side analysts anticipate that Histogenics Corp will post -0.71 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in shares of Histogenics by 72.0% in the 2nd quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 22,927 shares in the last quarter. DRW Securities LLC purchased a new position in shares of Histogenics in the 2nd quarter worth about $242,000. JPMorgan Chase & Co. purchased a new position in shares of Histogenics in the 1st quarter worth about $320,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Histogenics by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 22,133 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.
About Histogenics (NASDAQ:HSGX)
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Further Reading: Balance Sheet
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.